Skip to main content

Research Repository

Advanced Search

Outcome 1 year after ICH: Data from the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial

Law, Zhe Kang; Menon, Chaamanti Sivakumar; Woodhouse, Lisa J; Appleton, Jason Philip; Al-Shahi Salman, Rustam; Robinson, Thompson; Werring, David; Roffe, Christine; Dineen, Robert A; Bath, Philip Michael; Sprigg, Nikola

Outcome 1 year after ICH: Data from the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial Thumbnail


Authors

Zhe Kang Law

Jason Philip Appleton

Rustam Al-Shahi Salman

Thompson Robinson

David Werring

Christine Roffe

ROBERT DINEEN rob.dineen@nottingham.ac.uk
Professor of Neuroradiology

PHILIP BATH philip.bath@nottingham.ac.uk
Stroke Association Professor of Stroke Medicine

NIKOLA SPRIGG nikola.sprigg@nottingham.ac.uk
Professor of Stroke Medicine



Abstract

Introduction:
The Tranexamic acid for IntraCerebral Haemorrhage-2 (TICH-2) trial reported no significant improvement in death and dependency at day 90 despite reductions in haematoma expansion, early neurological deterioration and early death. However, significant recovery after stroke, particularly intracerebral haemorrhage (ICH), may take more than 3 months. Here we report the participant outcomes at 1 year after stroke.

Patients and methods:
TICH-2 was a prospective randomised controlled trial that tested the efficacy and safety of tranexamic acid in spontaneous ICH when given within 8 h of onset. Patients with ICH on anticoagulation were excluded. Centralised blinded telephone follow up was performed for patients from the United Kingdom at 1 year. The primary outcome was modified Rankin Scale at 1 year. Secondary outcomes included Barthel index, Telephone Interview Cognitive Status-modified, EuroQoL-5D and Zung Depression Scale. This was a prespecified secondary analysis of the TICH-2 trial.

Results:
About 2325 patients were recruited into the trial (age 68.9 ± 13.8 years; 1301 male, 56%). About 1910 participants (82.2%) were eligible for day 365 follow up. 57 patients (3.0%) were lost to follow up. Tranexamic acid did not reduce the risk of poor functional outcome at 1 year (adjusted OR 0.91 95% CI 0.77–1.09; p = 0.302). However, Cox proportional hazard analysis revealed significant survival benefit in the tranexamic acid group (adjusted HR 0.83, 95% CI 0.70–0.99; p = 0.038).

Conclusion:
There was no difference in functional outcome at 1 year after ICH. Tranexamic acid may reduce mortality at 1 year without an increase in severely dependent survivors. But this should be interpreted with caution as this is a result of secondary analysis in a neutral trial.

Citation

Law, Z. K., Menon, C. S., Woodhouse, L. J., Appleton, J. P., Al-Shahi Salman, R., Robinson, T., Werring, D., Roffe, C., Dineen, R. A., Bath, P. M., & Sprigg, N. (2024). Outcome 1 year after ICH: Data from the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial. European Stroke Journal, https://doi.org/10.1177/23969873241265939

Journal Article Type Article
Acceptance Date Jun 14, 2024
Online Publication Date Jul 30, 2024
Publication Date Jul 30, 2024
Deposit Date Jul 30, 2024
Publicly Available Date Jul 30, 2024
Journal European Stroke Journal
Electronic ISSN 2396-9873
Publisher SAGE Publications
Peer Reviewed Peer Reviewed
DOI https://doi.org/10.1177/23969873241265939
Public URL https://nottingham-repository.worktribe.com/output/37866401
Publisher URL https://journals.sagepub.com/doi/10.1177/23969873241265939

Files





You might also like



Downloadable Citations